| Annual · values | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | 100.00% | 100.00% | 99.19% | — | — | — | — | — | — |
| Operating Margin | 33.26% | 26.50% | -213.54% | 60.97% | 56.13% | 36.70% | 28.04% | -68.92% | -25.94% | -18.93% | -68.26% | -221.58% |
| EBITDA Margin | 33.63% | 26.84% | -213.27% | 61.31% | 56.50% | 37.29% | 29.35% | -67.15% | -23.13% | -15.18% | -60.48% | -205.45% |
| Net Margin | 8.11% | 0.25% | -226.37% | 42.64% | 127.72% | 27.26% | 5.02% | -81.46% | -39.20% | -29.83% | -95.40% | — |
| Current Ratio | 1.13 | 4.69 | 0.84 | 30.58 | 4.61 | 15.41 | 7.50 | 2.23 | 4.72 | 4.17 | 6.54 | 4.79 |
| Quick Ratio | 1.13 | 4.69 | 0.84 | 30.58 | 4.61 | 15.41 | 7.48 | 2.23 | 4.71 | 4.16 | 6.54 | 4.70 |
| Debt / Equity | -1.51 | -1.98 | -1.48 | 0.61 | 0.75 | 6.87 | — | — | — | — | 2.32 | — |
| ROE | -9.17% | -0.29% | 289.42% | 26.83% | 87.22% | 169.50% | -23.06% | 143.79% | -1187.42% | -122.47% | -149.98% | — |
| ROA | 6.05% | 0.25% | -212.76% | 15.91% | 46.89% | 18.99% | 5.34% | -85.04% | -19.31% | -11.51% | -23.04% | — |
| Asset Turnover | 0.75 | 1.00 | 0.94 | 0.37 | 0.37 | 0.70 | 1.06 | 1.04 | 0.49 | 0.39 | 0.24 | 0.23 |
| Book Value / Share | -1.61 | -1.88 | -2.23 | 3.50 | 3.69 | 0.39 | -0.60 | -1.29 | 0.07 | 0.46 | 0.67 | 0.65 |
Ironwood Pharmaceuticals Inc. is a healthcare and pharmaceuticals company specializing in the development and commercialization of drugs for gastrointestinal conditions. Headquartered in Cambridge, Massachusetts, Ironwood focuses on designing novel treatments that address unmet medical needs, particularly for conditions like irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). The company's flagship product is linaclotide, marketed under the brand name Linzess, which is a leading therapeutic option for IBS-C and CIC patients across the United States and several international markets. Ironwood Pharmaceuticals also engages in partnerships to enhance drug development and expand its market reach. Through a commitment to innovative research and strategic collaborations, Ironwood plays a significant role in the biotechnology sector, aiming to improve patient outcomes and health care experiences worldwide.